全文获取类型
收费全文 | 468篇 |
免费 | 26篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 19篇 |
妇产科学 | 29篇 |
基础医学 | 58篇 |
口腔科学 | 8篇 |
临床医学 | 30篇 |
内科学 | 94篇 |
皮肤病学 | 2篇 |
神经病学 | 17篇 |
特种医学 | 97篇 |
外科学 | 19篇 |
综合类 | 36篇 |
预防医学 | 15篇 |
眼科学 | 1篇 |
药学 | 32篇 |
中国医学 | 2篇 |
肿瘤学 | 36篇 |
出版年
2020年 | 4篇 |
2015年 | 4篇 |
2014年 | 9篇 |
2013年 | 16篇 |
2012年 | 12篇 |
2011年 | 10篇 |
2010年 | 19篇 |
2009年 | 11篇 |
2008年 | 11篇 |
2007年 | 15篇 |
2006年 | 11篇 |
2005年 | 13篇 |
2004年 | 14篇 |
2003年 | 10篇 |
2002年 | 19篇 |
2001年 | 11篇 |
2000年 | 10篇 |
1999年 | 7篇 |
1998年 | 11篇 |
1997年 | 15篇 |
1996年 | 13篇 |
1995年 | 5篇 |
1994年 | 14篇 |
1993年 | 5篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 18篇 |
1987年 | 19篇 |
1986年 | 30篇 |
1985年 | 14篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1982年 | 4篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 9篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1974年 | 5篇 |
1973年 | 5篇 |
1972年 | 2篇 |
1971年 | 4篇 |
1967年 | 3篇 |
1966年 | 7篇 |
1965年 | 3篇 |
1960年 | 2篇 |
排序方式: 共有496条查询结果,搜索用时 406 毫秒
51.
52.
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) 总被引:5,自引:0,他引:5
Gibson CM Singh KP Murphy SA DiBattiste PM Demopoulos LA Cannon CP Braunwald E;TIMI Study Group 《The American journal of cardiology》2004,94(4):492-494
In the setting of acute coronary syndromes, thrombotic embolization and activation of platelets with release of vasoconstrictors into the downstream microvasculature may occur before cardiac catheterization. In the Treat Angina with tirofiban and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18 (TACTICS-TIMI 18) trial angiographic substudy, a shorter duration of tirofiban infusion before percutaneous coronary intervention was associated with impaired myocardial perfusion before and after intervention. 相似文献
53.
Morrow DA de Lemos JA Sabatine MS Murphy SA Demopoulos LA DiBattiste PM McCabe CH Gibson CM Cannon CP Braunwald E 《Journal of the American College of Cardiology》2003,41(8):1264-1272
OBJECTIVES: This study was designed to evaluate B-type natriuretic peptide (BNP) for risk assessment and clinical decision making over a range of cut points, alone and with cardiac troponin I (cTnI), in patients with non-ST-elevation acute coronary syndromes (ACS). BACKGROUND: B-type natriuretic peptide holds promise for risk stratification. Additional evidence regarding optimal decision limits, use in combination with troponin, and use in targeting therapy is needed before acceptance into clinical use for ACS. METHODS: We evaluated BNP at baseline in 1,676 patients with non-ST-elevation ACS randomized to early invasive versus conservative management. RESULTS: Patients with elevated BNP (>80 pg/ml; n = 320) were at higher risk of death at seven days (2.5% vs. 0.7%, p = 0.006) and six months (8.4% vs. 1.8%, p < 0.0001). The association between BNP and mortality at six months (adjusted odds ratio [OR] 3.3; 95% confidence interval [CI] 1.7 to 6.3) was independent of important clinical predictors, including cTnI and congestive heart failure (CHF). Patients with elevated BNP had a fivefold higher risk of developing new CHF by 30 days (5.9% vs. 1.0%, p < 0.0001). B-type natriuretic peptide added prognostic information to cTnI, discriminating patients at higher mortality risk among those with negative (OR 6.9; 95% CI 1.9 to 25.8) and positive (OR 4.1; 95% CI 1.9 to 9.0) baseline cTnI results. No difference was observed in the effect of invasive versus conservative management when stratified by baseline levels of BNP (p(interaction) > or = 0.6). CONCLUSIONS: Elevated BNP (>80 pg/ml) at presentation identifies patients with non-ST-elevation ACS who are at higher risk of death and CHF and adds incremental information to cTnI. Additional work is needed to identify therapies that may reduce the risk associated with increased BNP. 相似文献
54.
Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation 总被引:3,自引:0,他引:3
In response to extracellular stimulation, one of the earliest events in human neutrophils is protein phosphorylation, which mediates signal transduction and leads to the regulation of cellular functions. Mitogen- activated protein (MAP) kinases are rapidly activated by a variety of mitogens, cytokines, and stresses. The activated MAP kinases in turn regulate their substrate molecules by phosphorylation. MAP kinase- activated protein (MAPKAP) kinase 2, a Ser/Thr kinase, has been shown to be phosphorylated by p38 MAP kinase both in vivo and in vitro. Phosphorylation of the Thr-334 site of MAPKAP kinase 2 results in a conformational change with subsequent activation of the enzyme. To better define the role of MAPKAP kinase 2 in the activation of human neutrophils, its enzymatic activity was measured after stimulation by either a phorbol ester (phorbol myristate acetate [PMA]), a potent protein kinase C activator, or the tripeptide fMLP, which is a chemotactic factor. The in vitro kinase assays indicate that both PMA and fMLP stimulated a transient increase in the enzymatic activity of cellular MAPKAP kinase 2. The induced kinase activation was concentration-dependent and reached a maximum at 5 minutes for PMA and 1 minute for fMLP. To identify potential substrate molecules for MAPKAP kinase 2, a highly active kinase mutant was generated by mutating the MAP kinase phosphorylation site in the C-terminal region. The replacement of threonine 334 with alanine resulted in a marked augmentation of catalytic activity. Analysis of in vitro protein phosphorylation in the presence of the active kinase indicates that a 60-kD cytosolic protein (p60) was markedly phosphorylated and served as the major substrate for MAPKAP kinase 2 in human neutrophils. Based on the MAPKAP kinase 2 phosphorylation site of Hsp27, a competitive inhibitory peptide was synthesized. This competitive inhibitory peptide specifically inhibited MAPKAP kinase 2 enzymatic activity, as well as the in vitro and in vivo kinase-induced p60 phosphorylation. To assess the contribution of MAPKAP kinase 2 in neutrophil function, the oxidative burst response after manipulation of endogenous kinase activity was measured. Intracellular delivery of the competitive inhibitory peptide into human neutrophils reduced both PMA- and fMLP- stimulated superoxide anion production. Thus, the results strongly suggest that MAPKAP kinase 2 is involved in the activation of human neutrophils. 相似文献
55.
56.
57.
Corpus callosum and limbic system: neuroanatomic MR evaluation of developmental anomalies 总被引:4,自引:0,他引:4
Atlas SW; Zimmerman RA; Bilaniuk LT; Rorke L; Hackney DB; Goldberg HI; Grossman RI 《Radiology》1986,160(2):355-362
Agenesis of the corpus callosum is a complex malformation of the brain that has been associated with varying degrees of limbic system maldevelopment. We retrospectively reviewed the records of 11 patients with callosal agenesis (seven total, four partial) who underwent magnetic resonance (MR) imaging, with particular attention to the associated malformations of the limbic system. Comparison was made with selected images from MR examinations of healthy volunteers and with necropsy specimens from other patients with callosal agenesis. Ten of 11 patients demonstrated limbic anomalies (severe motion artifact precluded evaluation of these structures in one patient). MR depicted not only the abnormalities intrinsic to callosal agenesis but also the frequently associated malformations of the limbic system. 相似文献
58.
59.
60.
Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy 总被引:23,自引:0,他引:23
White RI Jr; Lynch-Nyhan A; Terry P; Buescher PC; Farmlett EJ; Charnas L; Shuman K; Kim W; Kinnison M; Mitchell SE 《Radiology》1988,169(3):663-669
Over a 10-year period, 276 pulmonary arteriovenous malformations (PAVMs) were occluded with balloon embolotherapy in 76 patients, 67 (88%) of whom had hereditary hemorrhagic telangiectasia. Eleven patients (14%) were discovered by means of family screening with measurement of arterial blood gases and chest radiography. Epistaxis, dyspnea, hemoptysis, and hemothorax occurred in 79%, 71%, 13%, and 9% of patients, respectively. Clinical histories of strokes and transient ischemic attacks were present in 18% and 37% of patients, respectively. Computed tomographic scans of 59 patients showed stroke in 36%. Sixty-five percent of PAVMs were located in the lower lobes, which correlated with the finding of more pronounced hypoxemia in the upright position. After embolotherapy, symptomatic hypoxemia was corrected, and serial values have remained constant for 5 years. Complications were minimal, and no patient required surgery. Balloon embolotherapy is effective long-term therapy for PAVMs, and family screening should be pursued because of the possibility of a higher frequency of paradoxical embolization (stroke) than previously recognized. 相似文献